Member Login | Links

Society of Utah Medical Oncologists

Society of Utah Medical Oncologists

  • About Us
  • Membership
  • Practice Issues
  • News
    • All News
    • ACCC
    • ASCO
    • ASCO Alert
    • CMS Update
    • FDA
    • FDA Approval
    • Health Care
    • Medicare
    • NCCN Flash Updates
    • News Article
    • Oplinc
    • Patient Assistance
    • PQRI Standards for Oncology
    • Recall
    • United Healthcare
  • Legislation
  • Directory
  • Contact

Education • Collaboration • Advocacy

Improving the quality of patient care.

Advocating for patients & their families.

Connecting & uniting oncology in Utah.

Diamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberDiamond Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberPlatinum Corporate MemberGold Corporate MemberGold Corporate MemberGold Corporate MemberGold Corporate MemberGold Corporate MemberSilver Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate MemberBronze Corporate Member

Membership

signup

Education & Events

  • Your Practice and the Medicare Patient: Considerations for Access

    Online Presentation Sponsored by Genentech Presented by William Koch, Administrative Director Yvette Cordova, Practice Administrator GENENTECH WEBCAST Wednesday, April 04, 2018 Event Code: MF009531 Log-In Time: 12:00pm EST Event Code: MF009532 Log-In Time: 12pm CST Event Code: MF009533 Log-In Time: … Continued

  • Save the Date – Fall Meeting

    Sumo Fall Business meeting September 21-22, 2018 Hyatt Centric Park City 3551 N. Escala Court, Park City, UT 84098 435-940-1234 Registration information coming soon! Questions? E-Mail: [email protected] [email protected] Phone: 801-736-0086

All Education & Events >>

News

  • blinatumomab

    FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult … Continued

  • nilotinib

    FDA approves nilotinib for pediatric patients with newly diagnosed or resistant/intolerant Ph+ CML in chronic phase Food and Drug Administration approved nilotinib (TASIGNA, Novartis Pharmaceuticals  Corporation) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome … Continued

All News >>

Polls

  • This field is for validation purposes and should be left unchanged.
Twitter Facebook Connect with us!
Copyright 2008-2018© Society of Utah Medical Oncologists. All rights reserved
Privacy Policy | Terms of Use